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Dear editor,  
After previous evidence from the ASPIRE trial [1], results from TANGO study [2] definitively proved 
the efficacy of lamivudine (3TC) plus dolutegravir (DTG) as a maintenance strategy. As trials’ 
populations often differ from real-practice settings, we aimed to assess whether these results are 
reproducible in an unselected HIV-population. An observational longitudinal multicenter research 
study was conducted. HIV-positive patients with viral suppression (at least one HIV-RNA<50 
copies/mL) were followed-up from the start of 3TC+DTG. The cohort was divided into two groups 
based on compliance or not with the inclusion criteria of TANGO study (absence of HBV-coinfection, 
of previous virological failure (VF), of a M184V-harboring virus and of previous AIDS-event other 
than cutaneous Kaposi’s sarcoma and nadir CD4 count≤200 mm3).  
Time to VF (i.e. 2 consecutive HIV-RNA determinations ≥50 cps/mL or a single HIV-RNA≥1000 
cps/mL) and to treatment discontinuation (TD, i.e. the interruption of any of the study drugs) in the 
2 groups were compared through Kaplan-Meier with log-rank test and Cox-regression model after 
adjusting for the main clinical and demographic between-groups differences. Changes in 
immunological parameters were assessed by linear mixed model for repeated measures. 
We analyzed 557 patients with a median follow-up time of 22 months: 145 (26.0%) met the TANGO 
inclusion criteria (TANGO group, TG). They were mostly men (70.4%), of Caucasians ethnicity 
(92.1%). Characteristics of study groups are summarized in table 1. 
One VF over 248 PYFU and 11 VF over 776 PYFU occurred in the TG and non-TG, respectively. The 
estimated probability of maintaining virological suppression was 99.2% (SD±1.6) at 48, 96 and 144 
weeks in the TG, and 98.5% (SD±1.4) at 48 weeks, 97.7 (SD±1.8) at 96 weeks and 95.7% (SD±2.6) at 
144 weeks in the non-TG (log-rank p=0.189). After stratifying for the presence of M184V at historical 
genotype and for previous VF the results did not change (p=0.253 and p=0.186). Moreover, 
belonging to TG was not predictive of VF (aHR 0.35, 95%CI 0.04-2.84; p=0.327) after adjusting for 
age, anti-HCV serostatus and HIV duration. No resistance-associated mutations emerged after VF.  
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Estimated probabilities of remaining on 3TC+DTG were 86.6% (SD±5.9) at week 48 and 79.5% 
(SD±7.5) at both weeks 96 and 144 in the TG, and 85.8% (SD±3.5), 78.9% (SD±4.3) and 73.9% 
(SD±5.1) at weeks 48, 96 and 144 in the non-TG (log-rank p=0.654), with no significantly-increased  
hazard of TD for the TG (vs non-TG, aHR 0.97, 95%CI 0.60-1.57, p=0.894) after adjusting for 
confounders. A significant increase in CD4/CD8 ratio (mean change at 96 weeks, +0.05 in TG and 
+0.07 in non-TG) was observed over time, with no difference between groups.  
Previous studies on 3TC+DTG as a switch strategy reported low rate of VF in clinical practice [3,4]. 
However, some demographic and viro-immunological characteristics seemed to increase the risk of 
VF during 3TC+DTG [5], possibly limiting the widespread use of this strategy in experienced patients. 
Overall, our findings from clinical practice are in line with the TANGO study results. However, a 
higher, albeit not statistically-significant, number of VF was seen in the non-TG: pending results from 
longer follow-up studies, in our opinion caution should be advised when considering 3TC+DTG for 
selected patients (e.g., those with previous VF or shorter time of viral suppression). 
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Table 1. Baseline patients’ characteristics. 
 TANGO group 
(n=145) 
Non-TANGO 
group (n=412) 
P 
value 
Age (Years), Median (IQR) 49 (40-55) 53 (47-58) <0.001 
Male sex, n (%) 111 (76.6) 281 (68.2) 0.058 
Ethnicity, n (%): 
- Caucasians 
- Sub-Saharan 
- Central-South American 
- Other/unknown 
 
129 (89.0) 
4 (2.8) 
6 (4.1) 
6 (4.1) 
 
384 (93.2) 
14 (3.4) 
6 (1.5) 
8 (1.9) 
0.112 
Risk factor for HIV, n (%): 
- Heterosexual 
- MSM 
- IDU 
- Other/Unknown 
 
56 (38.6) 
37 (25.5)  
15 (10.4) 
37 (25.5) 
 
169 (41.0) 
108 (26.2) 
86 (20.9) 
49 (11.9) 
<0.001 
CDC Stage C, n (%) 20 (13.8) 62 (15.0) 0.854 
Anti HCV positive serostatus, n (%) 25 (17.2) 101 (24.5) 0.076 
Peak HIV-RNA (log10 copies/mL), median (IQR) 4.95 (4.45-5.35) 4.89 (4.37-5.43) 0.780 
Nadir CD4+ cell count (cells/mm3), median (IQR) 278 (140-395) 212 (93-309) 0.001 
Non-B HIV subtype, n (%) 5 (3.4) 13 (3.2) 0.875 
Years from HIV diagnosis, median (IQR) 9 (5-17) 18 (10-24) <0.001 
Years of cumulative ARVs exposure, median 
(IQR) 
7 (3-12) 13 (8-19) <0.001 
Months of virological suppression, median (IQR) 61.5 (31.5-103.1) 95.4 (51.5-126.9) <0.001 
Time of virological suppression≤6 months (%)  / 13 (3.2) NA 
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Baseline CD4+ cell count (cells/mm3), median 
(IQR) 
692 (453-912) 660 (500-876) 0.826 
Previous virological failure, n (%) / 223 (54.1) NA 
Previous ARV regimen, n (%): 
- 2NRTI + bPI 
- 2NRTI + NNRTI 
- 2NRTI + INI 
- Dual/Monotherapy 
- Other 
 
22 (15.2) 
90 (62.1) 
33 (22.7) 
0 (0) 
0 (0) 
 
55 (13.3) 
55 (13.3) 
57 (13.8) 
220 (53.4) 
25 (6.2) 
<0.001 
M184V resistance mutation detection at last  
genotipic resistance test, n (%) 
/ 45 (10.9) NA 
Reason for starting DTG+3TC, n (%): 
- Simplification/Proactive switch 
- Dyslipidemia 
- Toxicity GI tract 
- Renal toxicity 
- Osteopenia/osteoporosis 
- Other toxicity 
- Drug-drug interaction 
- Other/Unknown 
 
49 (33.8) 
5 (3.4) 
13 (9.0) 
13 (9.0) 
20 (13.8) 
10 (6.8) 
6 (4.1) 
29 (20.1) 
 
106 (25.7) 
87 (21.1) 
31 (7.5) 
18 (4.4) 
7 (1.7) 
10 (2.4) 
30 (7.3) 
123 (29.9) 
<0.001 
Notes: IQR, inter-quartile range; MSM, men who have sex with men; IDU, intravenous drug users; 
ARV, antiretroviral; (N)NRTI, (non) nucleoside-reverse transcriptase inhibitor; bPI, boosted-protease 
inhibitor; INI, integrase inhibitor; GI, gastro-intestinal. 
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